Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...

Mild side effects of Tremfya include injection site reactions and upper respiratory infections. Though rare, Tremfya can also cause serious side effects, including severe infections. Your doctor may ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

Johnson & Johnson has announced that the US Food and Drug Administration has approved its TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). A ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis ...

Tremfya interacts with other biologic immunomodulator drugs, such as abatacept (Orencia) and canakinumab (Ilaris). Tremfya can also interact with tricyclic antidepressants (TCAs), such as ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

The cost of Tremfya can vary depending on the form of the drug, your insurance coverage, and whether you receive injections at a doctor’s office or administer them yourself at home. Financial ...

Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...